格列本脲对平滑肌细胞及肌源性泡沫细胞内ACAT转录水平的影响  

The effect of glibenclamide on expression of ACAT mRNA of VSMCs and FCs

作　　者：成蓓[1] 狄鸣[2] 雷健[2] 戴康 马志强[4] 余其振[1] 王毅[5] 

机构地区：[1]华中科技大学同济医学院附属协和医院,湖北武汉430022 [2]武汉市第一医院,湖北武汉430033 [3]美国科罗拉多康复科学中心麻醉系,美国科罗拉多625014 [4]解放军第161医院,湖北武汉430020 [5]上海交通大学第一附属人民医院,上海200080

出　　处：《中国医院药学杂志》2006年第5期510-512,共3页Chinese Journal of Hospital Pharmacy

基　　金：国家自然科学基金项目(编号:30170378)

摘　　要：目的:研究格列本脲(glibenclamide,优降糖)对酰基辅酶A[胆固醇酰基转移酶(ACAT)]mRNA水平的影响,探讨其对ACAT酶的调节水平。方法:在小鼠主动脉平滑肌细胞及肌源性泡沫细胞分别加入格列本脲,孵育24h,用半定量RT-PCR检测ACAT酶mRNA表达。结果:(1)平滑肌细胞转变为泡沫细胞后,ACATmRNA的表达均增加。(2)格列本脲抑制平滑肌源性泡沫细胞中ACAT酶的mRNA的表达。结论:格列本脲在转录水平抑制ACATmRNA的表达,抑制平滑肌细胞向泡沫细胞的转化,可作为防止动脉粥样硬化的有效药物。OBJECTIVE To investigate the effect of glibenclamide on expression of acyl-CoA：cholesterol acyltransferase enzyme （ACAT） mRNA, and to discuss its regulating level. METHODS Mice aortic vascular smooth muscle cells （VSMCs） were cultured with 100 mg·L^-1 oxidized low density lipoprotein for 72 hours to form foam eells（FCs） derived from VSMCs. Both VSMCs and FCs derived from VSMCs were incubaled with glibenclamide for 24 hours, and ACAT mRNA was studied by semi-quantitative reverse transcription-polymerase chain reaction（RT-PCR） respectively. RESULTS （1） While VSMCs transformed into FCs, the expression of ACAT mRNA increased from 0. 20 - 0.07 to 0. 42 ± 0. 11）（P〈0.05）. （2）Glibenclamide inhibited the expression of ACAT mRNA, from 0. 42 ± 0. 10 to 0. 28 ± 0. 05, with significant difference （P〈0. 05）. CONCLUSION Glibenclamide decreases the expression of ACAT mRNA, prevents the formation of FCs derived from VSMCs,and can be used as an inhibitor of atherosclerosis.

关 键 词：胆固醇酰基转移酶 平滑肌细胞 泡沫细胞 格列本脲 动脉粥样硬化 

分 类 号：R965[医药卫生—药理学]